150 related articles for article (PubMed ID: 34418751)
1. Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling.
Whigham CA; Hastie R; Hannan NJ; Brownfoot F; Pritchard N; Cannon P; Nguyen TV; Kandel M; Masci J; Tong S; Kaitu'u-Lino TJ
Placenta; 2021 Oct; 114():22-28. PubMed ID: 34418751
[TBL] [Abstract][Full Text] [Related]
2. EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion.
Hastie R; Brownfoot FC; Pritchard N; Hannan NJ; Cannon P; Nguyen V; Palmer K; Beard S; Tong S; Kaitu'u-Lino TJ
Hypertension; 2019 Mar; 73(3):659-670. PubMed ID: 30636550
[TBL] [Abstract][Full Text] [Related]
3. Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction.
Brownfoot FC; Hannan NJ; Cannon P; Nguyen V; Hastie R; Parry LJ; Senadheera S; Tuohey L; Tong S; Kaitu'u-Lino TJ
EBioMedicine; 2019 Mar; 41():636-648. PubMed ID: 30824385
[TBL] [Abstract][Full Text] [Related]
4. Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling.
Hastie R; Brownfoot FC; Cannon P; Nguyen V; Tuohey L; Hannan NJ; Tong S; Kaitu'u-Lino TJ
Placenta; 2019 Nov; 87():53-57. PubMed ID: 31561065
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta.
Ye L; Gratton A; Hannan NJ; Cannon P; Deo M; Palmer KR; Tong S; Kaitu'u-Lino TJ; Brownfoot FC
Placenta; 2016 Dec; 48():110-118. PubMed ID: 27871461
[TBL] [Abstract][Full Text] [Related]
6. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ
Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405
[TBL] [Abstract][Full Text] [Related]
7. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome.
Hastie R; Ye L; Hannan NJ; Brownfoot FC; Cannon P; Nguyen V; Tong S; Kaitu'u-Lino TJ
Pregnancy Hypertens; 2018 Oct; 14():125-130. PubMed ID: 30527099
[TBL] [Abstract][Full Text] [Related]
8. Effects of sirtuin 1 deficiency on trophoblasts and its implications in the pathogenesis of pre-eclampsia.
Yu H; Chen L; Du P; Liu X; Xia Y
J Obstet Gynaecol; 2023 Dec; 43(2):2282103. PubMed ID: 37966393
[TBL] [Abstract][Full Text] [Related]
9. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
[TBL] [Abstract][Full Text] [Related]
10. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia.
Nagamatsu T; Fujii T; Kusumi M; Zou L; Yamashita T; Osuga Y; Momoeda M; Kozuma S; Taketani Y
Endocrinology; 2004 Nov; 145(11):4838-45. PubMed ID: 15284201
[TBL] [Abstract][Full Text] [Related]
11. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta.
Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Kaitu'u-Lino TJ
BMC Pregnancy Childbirth; 2016 May; 16():117. PubMed ID: 27207105
[TBL] [Abstract][Full Text] [Related]
12. Placental trophoblast-specific overexpression of chemerin induces preeclampsia-like symptoms.
Tan L; Chen Z; Sun F; Zhou Z; Zhang B; Wang B; Chen J; Li M; Xiao T; Neuman RI; Niu J; Verdonk K; Lu X; Zhang JV; Danser AHJ; Yang Q; Fan X
Clin Sci (Lond); 2022 Feb; 136(4):257-272. PubMed ID: 35103285
[TBL] [Abstract][Full Text] [Related]
13. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.
Ren Z; Cui N; Zhu M; Khalil RA
Am J Physiol Heart Circ Physiol; 2018 Jul; 315(1):H33-H47. PubMed ID: 29569955
[TBL] [Abstract][Full Text] [Related]
14. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies.
Gu Y; Lewis DF; Wang Y
J Clin Endocrinol Metab; 2008 Jan; 93(1):260-6. PubMed ID: 17956952
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products as an upstream molecule triggers ROS-induced sFlt-1 production in extravillous trophoblasts: a novel bridge between oxidative stress and preeclampsia.
Huang QT; Zhang M; Zhong M; Yu YH; Liang WZ; Hang LL; Gao YF; Huang LP; Wang ZJ
Placenta; 2013 Dec; 34(12):1177-82. PubMed ID: 24144948
[TBL] [Abstract][Full Text] [Related]
16. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
Holme AM; Roland MC; Henriksen T; Michelsen TM
Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
[TBL] [Abstract][Full Text] [Related]
17. Complement activation by an angiogenic imbalance leads to systemic vascular endothelial dysfunction: A new proposal for the pathophysiology of preeclampsia.
Matsuyama T; Tomimatsu T; Mimura K; Yagi K; Kawanishi Y; Kakigano A; Nakamura H; Endo M; Kimura T
J Reprod Immunol; 2021 Jun; 145():103322. PubMed ID: 33887508
[TBL] [Abstract][Full Text] [Related]
18. Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia.
Hannan NJ; Binder NK; Beard S; Nguyen TV; Kaitu'u-Lino TJ; Tong S
PLoS One; 2018; 13(4):e0187082. PubMed ID: 29641523
[TBL] [Abstract][Full Text] [Related]
19. Potency of Tokishakuyakusan in treating preeclampsia: Drug repositioning method by in vitro screening of the Kampo library.
Yagi K; Mimura K; Tomimatsu T; Matsuyama T; Kawanishi Y; Kakigano A; Nakamura H; Endo M; Kimura T
PLoS One; 2020; 15(12):e0244684. PubMed ID: 33378412
[TBL] [Abstract][Full Text] [Related]
20. Edaravone inhibits hypoxia-induced trophoblast-soluble Fms-like tyrosine kinase 1 expression: a possible therapeutic approach to preeclampsia.
Zhao Y; Zheng YF; Luo QQ; Yan T; Liu XX; Han L; Zou L
Placenta; 2014 Jul; 35(7):476-82. PubMed ID: 24840734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
